180 related articles for article (PubMed ID: 38245458)
21. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
Abdel-Razeq H; Sharaf B
Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
[TBL] [Abstract][Full Text] [Related]
22. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
23. Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands.
Luyendijk M; Blommestein H; Uyl-de Groot C; Siesling S; Jager A
JAMA Netw Open; 2023 Feb; 6(2):e2256170. PubMed ID: 36795415
[TBL] [Abstract][Full Text] [Related]
24. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
D'Angelo A; Giudici F; Chapman R; Darlow J; Kilili H; Sobhani N; Cinelli M; Cappelletti MR; Strina C; Milani M; Generali D
Curr Issues Mol Biol; 2022 Sep; 44(9):4255-4267. PubMed ID: 36135204
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
Ploumaki I; Triantafyllou E; Koumprentziotis IA; Karampinos K; Drougkas K; Karavolias I; Kotteas E
Clin Breast Cancer; 2024 Apr; 24(3):e177-e185. PubMed ID: 38320891
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
Sammons S; Moore H; Cushman J; Hamilton E
Expert Rev Anticancer Ther; 2022 Aug; 22(8):805-814. PubMed ID: 35737886
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 inhibition in early and metastatic breast cancer: A review.
de Groot AF; Kuijpers CJ; Kroep JR
Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
[TBL] [Abstract][Full Text] [Related]
30. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer.
Zhang C; Zhou F; Zou J; Fang Y; Liu Y; Li L; Hou J; Wang G; Wang H; Lai X; Xie L; Jiang J; Yang C; Huang Y; Chen Y; Zhang H; Li Y
Front Oncol; 2023; 13():1322078. PubMed ID: 38293701
[TBL] [Abstract][Full Text] [Related]
31. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
Giuliani J; Bonetti A
J Oncol Pharm Pract; 2020 Sep; 26(6):1486-1491. PubMed ID: 32576084
[TBL] [Abstract][Full Text] [Related]
32. Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence.
Polk A; Kolmos IL; Kümler I; Nielsen DL
ESMO Open; 2016; 1(6):e000093. PubMed ID: 28848657
[TBL] [Abstract][Full Text] [Related]
33. First-line CDK4/6 inhibitor-based combinations for HR+/HER2- advanced breast cancer: A Bayesian network meta-analysis.
Guo X; Zhou Y; Zhang K; Lu W; Zhong X; Wu S; Shen L; Chen H; Chen Y
J Evid Based Med; 2024 Mar; 17(1):106-118. PubMed ID: 38102891
[TBL] [Abstract][Full Text] [Related]
34. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
[TBL] [Abstract][Full Text] [Related]
35. Ribociclib plus fulvestrant in the treatment of breast cancer.
Neven P; Sonke GS; Jerusalem G
Expert Rev Anticancer Ther; 2021 Jan; 21(1):93-106. PubMed ID: 33085548
[TBL] [Abstract][Full Text] [Related]
36. Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.
Abdel-Razeq H; Sharaf B; AlMasri R; Abdel-Razeq R; Tamimi F; Khader O; Salama O; Abunasser M; Edaily S; Abdulelah H
Cancer Manag Res; 2022; 14():1033-1041. PubMed ID: 35300061
[TBL] [Abstract][Full Text] [Related]
37. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer.
Sobhani N; Fassl A; Mondani G; Generali D; Otto T
Cells; 2021 Feb; 10(2):. PubMed ID: 33535617
[TBL] [Abstract][Full Text] [Related]
38. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
39. Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
Iorfida M; Mazza M; Munzone E
Breast Cancer (Dove Med Press); 2020; 12():45-56. PubMed ID: 32256106
[TBL] [Abstract][Full Text] [Related]
40. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]